HCV Treatment
EASL 2016: Adolescents with Hepatitis C Achieve High Cure Rates with Sofosbuvir/Ledipasvir
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 22 April 2016 00:00
- Written by Liz Highleyman
Sofosbuvir/ledipasvir (Harvoni) was well-tolerated and led to sustained virological response in 97% of adolescents (age 12-17) with chronic hepatitis C, with high cure rates regardless of prior treatment experience or presence of liver cirrhosis, according to a report presented at the 2016 EASL International Liver Congress in Barcelona.
Coverage of the 2016 EASL International Liver Congress
- Details
- Category: HCV Treatment
- Published on Friday, 22 April 2016 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2016 European Association for the Study of the Liver International Liver Congress (EASL 2016) in Barcelona, April 13-17, 2016.
Conference highlights include interferon-free hepatitis C treatment for people with advanced disease, experimental HCV therapy, new treatment for hepatitis B, and management of liver disease complications.
International Liver Congress website
4/22/16
EASL 2016: Shifting Hepatitis C Treatment to Primary Care Providers Could Expand Availability
- Details
- Category: HCV Treatment
- Published on Friday, 15 April 2016 00:00
- Written by Liz Highleyman
Hepatitis C treatment managed by non-specialists such as primary care physicians and nurse practitioners is as safe and effective as treatment delivered by specialists -- even for challenging patient groups -- and could help increase the number of people receiving therapy, according to findings from the ASCEND study presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this week in Barcelona.
EASL 2016: Novel Therapy RG-101 Plus Antivirals Could Cure Hepatitis C in 4 Weeks
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 18 April 2016 00:00
- Written by Liz Highleyman
Two injections of RG-101, an experimental drug that targets the micro RNA miR-122 in liver cells, combined with direct-acting antiviral agents (DAAs) taken for just 4 weeks led to 12-week post-treatment sustained response in 97% of chronic hepatitis C patients, according to study results presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last week in Barcelona.
EASL 2016: $300 Hepatitis C Combination with Ravidasvir to Enter Clinical Trials
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 15 April 2016 00:00
- Written by Keith Alcorn
The Drugs for Neglected Diseases Initiative (DNDi) is launching clinical trials in Thailand and Malaysia to test a combination of sofosbuvir and ravidasvir, an NS5A inhibitor, in at least 800 people with all genotypes of hepatitis C virus (HCV). The combination, manufactured by Egyptian company Pharco, could be made available for $300 for a course of treatment if it proves safe and effective, DNDi executive director Bernard Pécoul announced ahead of the 2016 EASL International Liver Congress this week in Barcelona. The studies will aim to test an affordable pangenotypic combination and to provide data for regulatory submission.
Web Design and Development by